Fundamental Immune-Oncogenicity Trade-Offs Define Driver Mutation Fitness

Scientists developed a model that anticipated patient survival in The Cancer Genome Atlas and patients with lung cancer treated with immunotherapy as well as the age of tumor onset in germline carriers of TP53 variants.